Telix Pharmaceuticals Files Q1 2026 Business Update
Ticker: TLX · Form: 6-K · Filed: 2026-04-07T06:27:27-04:00
Sentiment: neutral
Topics: quarterly-report, business-update, foreign-issuer
TL;DR
Telix dropped its Q1 2026 business update on 4/7/26 - check EX-99.1 for deets.
AI Summary
Telix Pharmaceuticals Ltd. filed a 6-K report on April 7, 2026, for the period ending March 31, 2026. The filing includes a business update for the first quarter of 2026, with detailed financial and operational information presented in an attached exhibit (EX-99.1). The report is from a foreign issuer and contains graphic elements.
Why It Matters
This filing provides investors with a quarterly update on Telix Pharmaceuticals' business performance and financial standing, crucial for assessing the company's progress and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly filing (6-K) providing business updates, not indicating any immediate or significant new risks.
Key Players & Entities
- Telix Pharmaceuticals Ltd (company) — Filer
- 0002007191 (company) — CIK number
- 2026-04-07 (date) — Filing Date
- 2026-03-31 (date) — Period of Report
- EX-99.1 (document) — Business update exhibit
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report business updates for Telix Pharmaceuticals Ltd. for the period ending March 31, 2026.
When was this filing accepted by the SEC?
This filing was accepted by the SEC on April 7, 2026.
What is the accession number for this filing?
The SEC accession number for this filing is 0001628280-26-023982.
Which exhibit contains the Q1 2026 business update?
Exhibit EX-99.1 contains the Q1 2026 business update.
What is the CIK number for Telix Pharmaceuticals Ltd?
The CIK number for Telix Pharmaceuticals Ltd is 0002007191.
From the Filing
EDGAR Filing Documents for 0001628280-26-023982 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: SEC Accession No. 0001628280-26-023982 Filing Date 2026-04-07 Accepted 2026-04-07 06:27:27 Documents 3 Period of Report 2026-03-31 Document Format Files Seq Description Document Type Size 1 6-K telix-6kforq1businessrelea.htm 6-K 20403 2 EX-99.1 q1businessupdate.htm EX-99.1 168215 3 image_01.jpg GRAPHIC 76043 Complete submission text file 0001628280-26-023982.txt 293851 Mailing Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 Business Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 61 3 9093 3855 Telix Pharmaceuticals Ltd (Filer) CIK : 0002007191 (see all company filings) EIN. : 000000000 | State of Incorp.: C3 | Fiscal Year End: 1231 Type: 6-K | Act: 34 | File No.: 001-42128 | Film No.: 26842867 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)